COMPARISON OF PURE ANTIBODY-MEDIATED REJECTION (AMR) WITH MIXED CELLULAR AND AMR IN REGARDS TO THE DEVELOPMENT OF CARDIAC ALLOGRAFT VASCULOPATHY (CAV) AND CARDIOVASCULAR MORTALITY (CVM) IN HEART TRANSPLANT PATIENTS